{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T17:04:40Z","timestamp":1784653480377,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["advancesinpediatrics.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Pediatrics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.yapd.2025.12.013","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T19:58:50Z","timestamp":1779911930000},"page":"65-81","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pain Management in Pediatric Patients with Sickle Cell Disease"],"prefix":"10.1016","volume":"73","author":[{"given":"Marni","family":"Shear","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moran","family":"Gotesman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yapd.2025.12.013_bib1","series-title":"Addressing sickle cell disease: a strategic plan and blueprint for action","year":"2020"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26758","article-title":"An analysis of inpatient pediatric sickle cell disease: incidence, costs, and outcomes","volume":"65","author":"Bou-Maroun","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib3","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1542\/pir.2022-005631","article-title":"Management of acute sickle cell disease pain","volume":"45","author":"Payne","year":"2024","journal-title":"Pediatr Rev"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"10.1016\/j.yapd.2025.12.013_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ejh.13430","article-title":"The vaso-occlusive pain crisis in sickle cell disease: definition, pathophysiology, and management","volume":"105","author":"Darbari","year":"2020","journal-title":"Eur J Haematol"},{"issue":"11","key":"10.1016\/j.yapd.2025.12.013_bib6","doi-asserted-by":"crossref","first-page":"e787","DOI":"10.1016\/S2352-3026(20)30333-1","article-title":"Life is a PAINting","volume":"7","author":"Nazaire","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.yapd.2025.12.013_bib7","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jpain.2018.12.003","article-title":"AAAPT diagnostic criteria for acute sickle cell disease pain","volume":"20","author":"Field","year":"2019","journal-title":"J Pain"},{"issue":"2","key":"10.1016\/j.yapd.2025.12.013_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1177\/2049463720920682","article-title":"Mechanisms of pain in sickle cell disease","volume":"15","author":"Takaoka","year":"2021","journal-title":"Br J Pain"},{"issue":"5","key":"10.1016\/j.yapd.2025.12.013_bib9","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jpain.2016.12.016","article-title":"AAPT diagnostic criteria for chronic sickle cell disease pain","volume":"18","author":"Dampier","year":"2017","journal-title":"J Pain"},{"issue":"5","key":"10.1016\/j.yapd.2025.12.013_bib10","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2024-068752","article-title":"Opioid prescribing for acute pain management in children and adolescents in outpatient settings: clinical practice guideline","volume":"154","author":"Hadland","year":"2024","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1182\/hematology.2020000143","article-title":"Optimizing the management of chronic pain in sickle cell disease","volume":"2020","author":"Osunkwo","year":"2020","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib12","first-page":"553","article-title":"Neuropathic pain in sickle cell disease: measurement and management","volume":"2020","author":"Glaros","year":"2020","journal-title":"Hematology"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jpain.2023.07.029","article-title":"Biopsychosocial factors associated with pain and pain-related outcomes in adults and children with sickle cell disease: a multivariable analysis of the GRNDaD multicenter registry","volume":"25","author":"Kenney","year":"2024","journal-title":"J Pain"},{"issue":"4","key":"10.1016\/j.yapd.2025.12.013_bib14","first-page":"1029","article-title":"The management of pain in sickle cell disease","volume":"36","author":"Shapiro","year":"1989","journal-title":"Pediatr Clin"},{"key":"10.1016\/j.yapd.2025.12.013_bib54","doi-asserted-by":"crossref","unstructured":"Brandow A.M., DeBaun M.R., Key components of pain management for children and adults with sickle cell disease, Hematology\/Oncology Clinics, 32 (3), 2018, 535 - 550.","DOI":"10.1016\/j.hoc.2018.01.014"},{"issue":"2","key":"10.1016\/j.yapd.2025.12.013_bib16","first-page":"192","article-title":"Depression and anxiety in adults with sickle cell disease: the PiSCES project","volume":"70","author":"Levenson","year":"2008","journal-title":"Biopsychosocial Science and Medicine"},{"issue":"4","key":"10.1016\/j.yapd.2025.12.013_bib17","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/ajh.26063","article-title":"Impact of sickle cell disease on patients\u02bc daily lives, symptoms reported, and disease management strategies: results from the international Sickle Cell World Assessment Survey (SWAY)","volume":"96","author":"Osunkwo","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.yapd.2025.12.013_bib18","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2024-066842","article-title":"Health supervision for children and adolescents with sickle cell disease: clinical report","volume":"154","author":"Yates","year":"2024","journal-title":"Pediatrics"},{"issue":"10","key":"10.1016\/j.yapd.2025.12.013_bib19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yawn","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib20","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle cell disease: a review","volume":"328","author":"Kavanagh","year":"2022","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.yapd.2025.12.013_bib36","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/bloodadvances.2020001851","article-title":"American Society of Hematology 2020 guidelines for sickle cell disease: management of acute and chronic pain","volume":"4","author":"Brandow","year":"2020","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.yapd.2025.12.013_bib52","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/jha2.188","article-title":"Gabapentin for acute pain in sickle cell disease: a randomized double-blinded placebo-controlled phase II clinical trial","volume":"2","author":"Puri","year":"2021","journal-title":"EJHaem"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib53","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/MPH.0000000000000265","article-title":"The use of neuropathic pain drugs in children with sickle cell disease is associated with older age, female sex, and longer length of hospital stay","volume":"37","author":"Brandow","year":"2015","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib21","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/hematology.2024000587","article-title":"Practical guide for disease-modifying medication management of children and adolescents with sickle cell disease","volume":"2024","author":"Walden","year":"2024","journal-title":"Hematology"},{"issue":"11","key":"10.1016\/j.yapd.2025.12.013_bib22","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea therapy for sickle cell anemia","volume":"14","author":"McGann","year":"2015","journal-title":"Expet Opin Drug Saf"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jpeds.2014.01.070","article-title":"Sickle cell anemia: an underappreciated and unaddressed contributor to global childhood mortality","volume":"165","author":"McGann","year":"2014","journal-title":"J Pediatr"},{"issue":"3","key":"10.1016\/j.yapd.2025.12.013_bib24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease","volume":"379","author":"Niihara","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib25","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/MPH.0000000000002519","article-title":"Evaluation of glutamine utilization in patients with sickle cell disease","volume":"45","author":"Wu","year":"2023","journal-title":"J Pediatr Hematol Oncol"},{"issue":"4","key":"10.1016\/j.yapd.2025.12.013_bib26","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.21873\/invivo.12889","article-title":"Pediatric patients with sickle cell disease at a public hospital: nutrition, compliance and early experience with L-glutamine therapy","volume":"36","author":"Gotesman","year":"2022","journal-title":"in vivo"},{"issue":"5","key":"10.1016\/j.yapd.2025.12.013_bib28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.yapd.2025.12.013_bib29","unstructured":"Novartis A. Novartis provides update on Phase III STAND trial assessing crizanlizumab. 2023."},{"key":"10.1016\/j.yapd.2025.12.013_bib30","doi-asserted-by":"crossref","DOI":"10.1177\/23247096231191873","article-title":"Successful treatment of SCD-related priapism with crizanlizumab: a case series","volume":"11","author":"Idowu","year":"2023","journal-title":"Journal of Investigative Medicine High Impact Case Reports"},{"issue":"3","key":"10.1016\/j.yapd.2025.12.013_bib31","doi-asserted-by":"crossref","first-page":"105","DOI":"10.14740\/jh1127","article-title":"Real-world data of crizanlizumab in sickle cell disease: a single-center analysis","volume":"12","author":"Cheplowitz","year":"2023","journal-title":"Journal of Hematology"},{"issue":"6","key":"10.1016\/j.yapd.2025.12.013_bib34","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.yapd.2025.12.013_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/17474086.2022.2031967","article-title":"Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis","volume":"15","author":"Shah","year":"2022","journal-title":"Expert review of hematology"},{"issue":"11","key":"10.1016\/j.yapd.2025.12.013_bib37","first-page":"1548","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood, The Journal of the American Society of Hematology"},{"key":"10.1016\/j.yapd.2025.12.013_bib38","doi-asserted-by":"crossref","DOI":"10.1177\/09636897241246351","article-title":"Hematopoietic stem cell transplantation in sickle cell disease: a multidimentional review","volume":"33","author":"Rostami","year":"2024","journal-title":"Cell Transplant"},{"issue":"25","key":"10.1016\/j.yapd.2025.12.013_bib39","first-page":"2249","article-title":"How I treat sickle cell disease with hematopoietic cell transplantation","volume":"134","author":"Stenger","year":"2019","journal-title":"Blood, The Journal of the American Society of Hematology"},{"issue":"26","key":"10.1016\/j.yapd.2025.12.013_bib40","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1182\/blood.2024024519","article-title":"How I treat sickle cell disease with gene therapy","volume":"144","author":"Sharma","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.yapd.2025.12.013_bib41","unstructured":"Evidence-based management of sickle-cell disease: Expert Panel Report 2014. 2014."},{"key":"10.1016\/j.yapd.2025.12.013_bib55","doi-asserted-by":"crossref","unstructured":"Udezue E., Girshab A.M., Observations on the management of acute pain crisis in adult sickle cell disease in eastern Saudi Arabia, Ann Saudi Med, 25 (2), 2005, 115 - 119.","DOI":"10.5144\/0256-4947.2005.115"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib43","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/hematology.2024000585","article-title":"Beyond IV push: alternative methods for management of acute pain in SCD","volume":"2024","author":"Azul","year":"2024","journal-title":"Hematology"},{"issue":"2","key":"10.1016\/j.yapd.2025.12.013_bib44","doi-asserted-by":"crossref","first-page":"145","DOI":"10.36076\/ppj.2011\/14\/145","article-title":"A comprehensive review of opioid-induced hyperalgesia","volume":"14","author":"Lee","year":"2011","journal-title":"Pain Physician"},{"key":"10.1016\/j.yapd.2025.12.013_bib45","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.trsl.2021.03.007","article-title":"Pain in sickle cell disease: current and potential translational therapies","volume":"234","author":"Sagi","year":"2021","journal-title":"Transl Res"},{"issue":"5","key":"10.1016\/j.yapd.2025.12.013_bib46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jpain.2016.01.475","article-title":"An evaluation of central sensitization in patients with sickle cell disease","volume":"17","author":"Campbell","year":"2016","journal-title":"J Pain"},{"issue":"14","key":"10.1016\/j.yapd.2025.12.013_bib58","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1007\/s11606-023-08392-0","article-title":"The bias of medicine in sickle cell disease","volume":"38","author":"Anderson","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"5","key":"10.1016\/j.yapd.2025.12.013_bib47","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/phar.2676","article-title":"Buprenorphine initiation strategies for opioid use disorder and pain management: a systematic review","volume":"42","author":"Spreen","year":"2022","journal-title":"Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.yapd.2025.12.013_bib48","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.suponc.2012.05.002","article-title":"Twelve reasons for considering buprenorphine as a frontline analgesic in the management of pain","volume":"10","author":"Davis","year":"2012","journal-title":"J Support Oncol"},{"issue":"5","key":"10.1016\/j.yapd.2025.12.013_bib49","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.jpainsymman.2021.04.007","article-title":"Buprenorphine for chronic pain in a pediatric patient with sickle-cell disease","volume":"62","author":"Irwin","year":"2021","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"10.1016\/j.yapd.2025.12.013_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28766","article-title":"Ambulatory microdose induction of buprenorphine-naloxone in two adolescent patients with sickle cell disease","volume":"68","author":"Buchheit","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.yapd.2025.12.013_bib59","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31731","article-title":"Treatment experience using a micro-induction buprenorphine protocol for chronic pain in pediatric sickle cell disease","volume":"72","author":"Patel","year":"2025","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.yapd.2025.12.013_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpain.2024.104603","article-title":"Unmet need: mechanistic and translational studies of sickle cell disease pain as a whole-person health challenge","volume":"25","author":"Belfer","year":"2024","journal-title":"J Pain"}],"container-title":["Advances in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S006531012500043X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S006531012500043X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T16:30:43Z","timestamp":1784651443000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S006531012500043X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S006531012500043X"],"URL":"https:\/\/doi.org\/10.1016\/j.yapd.2025.12.013","relation":{},"ISSN":["0065-3101"],"issn-type":[{"value":"0065-3101","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pain Management in Pediatric Patients with Sickle Cell Disease","name":"articletitle","label":"Article Title"},{"value":"Advances in Pediatrics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yapd.2025.12.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}